Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-β1 secretion and enhances the anti-proliferative effect of 5-fluorouracil

British Journal of Pharmacology

Volumn 157, Issue 3, 2009, Pages 362-370

  Bourikas, Leonidas A ^a   Kolios, George ^b,d   Valatas, Vassilis ^a   Notas, George ^a   Drygiannakis, Ioannis ^a   Pelagiadis, Iordanis ^c   Manousou, Pinelopi ^a   Klironomos, Stefanos ^a   Mouzas, Ioannis A ^a   Kouroumalis, Elias ^a  

^a Department of Gastroenterology ^*  (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

Author keywords

Chemoprevention; Ciprofloxacin; HT 29 cells; Immunomodulation; Inflammatory bowel disease; TGF 1 colon cancer

Indexed keywords

CIPROFLOXACIN; FLUOROURACIL; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; ANTIINFECTIVE AGENT; ANTINEOPLASTIC ANTIMETABOLITE; IMMUNOLOGIC FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRAIN HT29; CELL SURVIVAL; COLON ADENOCARCINOMA; COLON MUCOSA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; EPITHELIUM CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; UPREGULATION; CELL STRAIN CACO 2; COLON; COMPARATIVE STUDY; CYTOLOGY; INTESTINE MUCOSA; SECRETION;

ANTI-INFECTIVE AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; CACO-2 CELLS; CELL PROLIFERATION; CELL SURVIVAL; CIPROFLOXACIN; COLON; DRUG SYNERGISM; FLUOROURACIL; HT29 CELLS; HUMANS; IMMUNOLOGIC FACTORS; INTESTINAL MUCOSA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70349904886     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00161.x     Document Type: Article

References (46)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): Sl209.
2. Aranha O, Wood DPJr, Sarkar FH (2000). Ciprofloxacin mediated cell growth inhibition, S/G2-M cell cycle arrest, and apoptosis in a human transitional cell carcinoma of the bladder cell line. Clin Cancer Res 6: 891-900. (Pubitemid 30159346)
3. Aranha O, Zhu L, Alhasan S, Wood DPJr, Kuo, TH, Sarkar FH (2002). Role of mitochondria in ciprofloxacin induced apoptosis in bladder cancer cells. J Urol 167: 1288-1294. (Pubitemid 34132072)
4. Becker C, Fantini MC, Neurath MF (2006). TGF-beta as a T cell regulator in colitis and colon cancer. Cytokine Growth Factor Rev 17: 97-106. (Pubitemid 43117519)
5. Bergeron MG (1989). The pharmacokinetics and tissue penetration of the fluoroquinolones. Clin Invest Med 12: 20-27.
6. Biasi F, Tessitore L, Zanetti D, Cutrin JC, Zingaro B, Chiarpotto E et al. (2002). Associated changes of lipid peroxidation and transforming growth factor betal levels in human colon cancer during tumour progression. Gut 50: 361-367. (Pubitemid 34161052)
7. Bierie B, Moses HL (2006). Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520. (Pubitemid 43980540)
8. Chen A, Davis BH, Sitrin MD, Brasitus TA, Bissonnette M (2002). Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1, 25(OH)(2)D(3). Am J Physiol Gastrointest Liver Physiol 283: G864-G874. (Pubitemid 35033929)
9. Crump B, Wise R, Dent J (1983). Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother 24: 784-786.
10. Dalhoff A, Shalit I (2003). Immunomodulatory effects of quinolones. Lancet Infect Dis 3: 359-371.
11. Derynck R, Akhurst RJ, Balmain A (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129. (Pubitemid 32952643)
12. El-Rayes BF, Grignon R, Aslam N, Aranha O, Sarkar FH (2002). Ciprofloxacin inhibits cell growth and synergises the effect of etoposide in hormone resistant prostate cancer cells, hit J Oncol 21: 207-211.
13. Elliott RL, Blobe GC (2005). Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093. (Pubitemid 46211385)
14. Forsgren A, Schlossman SF, Tedder TF (1987). 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. Antimicrob Agents Chemother 31: 768-773. (Pubitemid 17070737)
15. Greenberg GR (2004). Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm Bowel Dis 10: 318-320. (Pubitemid 38618264)
16. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D (2002). Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. BrJ Cancer 86: 443-448. (Pubitemid 34185131)
17. Herold C, Ganslmayer M, Ocker M, Blauberger S, Zopf S, Hahn EG et al. (2003). Overadditive anti-proliferative and pro-apoptotic effects of a combination therapy on colorectal carcinoma cells. Int J Oncol 23: 751-756.
18. Holtom PD, Pavkovic SA, Bravos PD, Patzakis MJ, Shepherd LE, Frenkel B (2000). Inhibitory effects of the quinolone antibiotics trovafloxacin, ciprofloxacin, and levofloxacin on osteoblastic cells in vitro. J. Orthop Res 18: 721-727.
19. Kamat AM, Lamm DL (2004). Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63: 457-460.
20. Kolios G, Manousou P, Bourikas L, Notas G, Tsagarakis N, Mouzas I et al. (2006). Ciprofloxacin inhibits cytokine-induced nitric oxide production in human colonic epithelium. Eur J Clin Invest 36: 720-729. (Pubitemid 44393931)
21. Kucharzik T, Lugering N, Winde G, Domschke W, Stall R (1997). Colon carcinoma cell lines stimulate monocytes and lamina propria mononuclear cells to produce IL-10. Clin Exp Immunol 110: 296-302. (Pubitemid 27469605)
22. Lahat G, Halperin D, Barazovsky E, Shalit I, Rabau M, Klausner J et al. (2007). Immunomodulatory effects of ciprofloxacin in TNBSinduced colitis in mice. Inflamm Bowel Dis 13: 557-565. (Pubitemid 46799639)
23. Lawrence JW, Claire DC, Weissig V, Rowe TC (1996). Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacintreated mammalian cells. Mol Pharmacol 50: 1178-1188. (Pubitemid 26384856)
24. Letterio JJ, Roberts AB (1998). Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137-161.
25. Madu AA, Mayers M, Perkins R, Liu W, Drusano GL, Aswani R et al. (1996). Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration. Exp Eye Res 63: 129-136. (Pubitemid 26273860)
26. Manning AM, Williams AC, Game SM, Paraskeva C (1991). Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta. Oncogene 6: 1471-1476.
27. Matsushita M, Matsuzaki K, Date M, Watanabe T, Shibano K, Nakagawa T et al. (1999). Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 80: 194-205. (Pubitemid 29210106)
28. Miclau T, Edin ML, Lester GE, Lindsey RW, Dahners LE (1998). Effect of ciprofloxacin on the proliferation of osteoblast-like MG-63 human osteosarcoma cells in vitro. J Orthop Res 16: 509-512. (Pubitemid 28427703)
29. Mosmann T (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
30. Naber KG, Sorgel F, Kinzig M, Weigel DM (1993). Penetration of ciprofloxacin into prostatic fluid, ejaculate and seminal fluid in volunteers after an oral dose of 750 mg. J Urol 150: 1718-1721. (Pubitemid 24346933)
31. Nita ME, Nagawa H, Tominaga O, Tsuno N, Fujii S, Sasaki S et al. (1998). 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br J Cancer 78: 986-992. (Pubitemid 28463972)
32. Norris MD, Madafiglio J, Gilbert J, Marshall GM, Haber M (2001). Reversal of multidrug resistance-associated protein-mediated drug resistance in cultured human neuroblastoma cells by the quinolone antibiotic difloxacin. Med Pediatr Oncol 36: 177-180.
33. Oldfield EC 3rd, Wallace MR (2001). The role of antibiotics in the treatment of infectious diarrhea. Gastroenterol Clin North Am 30: 817-836.
34. Rabau M, Nyska A, Dayan D (1995). In vitro effect of ciprofloxacin on HT-29 human colon carcinoma cell line: assessment of cell proliferation by thymidine uptake and silver nucleolar organizer regions (AgNOR) histomorphometry. Arch Toxicol 70: 124-126. (Pubitemid 26011369)
35. Riesbeck K (2002). Immunomodulating activity of quinolones: review. J Chemother 14: 3-12.
36. Riesbeck K, Bredberg A, Forsgren A (1990). Ciprofloxacin does not inhibit mitochondrial functions but other antibiotics do. Antimicrob Agents Chemother 34: 167-169. (Pubitemid 20019986)
37. Seay TM, Peretsman SJ, Dixon PS (1996). Inhibition of human transitional cell carcinoma in vitro proliferation by fluoroquinolone antibiotics. J Urol 155: 757-762. (Pubitemid 26023598)
38. Seoane J (2006). Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 27: 2148-2156.
39. Shah A, Lettieri J, Kaiser L, Echols R, Heller AH (1994). Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily. J Antimicrob Chemother 33: 795-801. (Pubitemid 24149815)
40. Shen LL (1994). Molecular mechanisms of DNA gyrase inhibition by quinolone antibacterials. Adv Pharmacol 29A: 285-304.
41. Siegel PM, Massague J (2003). Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
42. Somekh E, Douer D, Shaked N, Rubinstein E (1989). In vitro effects of ciprofloxacin and Pefloxacin on growth of normal human hematopoietic progenitor cells and on leukemic cell lines. J Pharmacol Exp Ther 248: 415-418. (Pubitemid 19063521)
43. Valatas V, Kolios G, Manousou P, Notas G, Xidakis C, Diamantis I et al. (2004). Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells. Br J Pharmacol 141: 477-487. (Pubitemid 38297010)
44. Weidekamm E, Portmann R (1993). Penetration of fleroxacin into body tissues and fluids. Am J Med 94: 75S-80S. (Pubitemid 23089432)
45. Wolfson JS, Hooper DC (1991). Pharmacokinetics of quinolones: newer aspects. Eur J Clin Microbiol Infect Dis 10: 267-274.
46. Zanetti D, Poli G, Vizio B, Zingaro B, Chiarpotto E, Biasi F (2003). 4-hydroxynonenal and transforming growth factor-betal expression in colon cancer. Mol Aspects Med 24: 273-280. (Pubitemid 36945027)